Celecoxib (Celebrex) in the Management of Acute Renal Colic

NCT ID: NCT00304317

Last Updated: 2017-01-24

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-03-31
• Study Completion Date: 2008-08-31

Brief Summary

The purpose of this trial is to quantify the amount Celebrex, a specific cyclooxygenase-2 (COX-2) inhibitor, when used for the management of acute renal colic for a ureteral stone will:

• reduce pain medication usage
• improve the percentage of spontaneous stone passage
• decrease the time to spontaneous passage, and
• shift the size distribution of stones passed towards larger sizes

Detailed Description

The study will be conducted as a prospective, randomized, double-blind controlled clinical trial. One-hundred and fifty-four patients with symptoms of acute renal colic and a ureteral calculus less than 10 mm in largest diameter on flat plain abdominal x-ray (KUB) or non-contrast computer tomography (CT) scan will be randomized in this trial. At the time of presentation with acute renal colic to the Emergency Department, the patient will be recruited for involvement. After informed consent, patients will be provided either 200 mg of Celebrex or a placebo equivalent. They will be instructed to follow the recommended dosing regimen for acute pain, taking two tablets in the emergency room (400 mg), followed by one tablet 12 hours later (200 mg), then one tablet twice a day for 10 days. Patients will be provided a prescription for Vicodin (1-2 tablets of 5/500 every 4-6 hours) to be taken as required for pain. Throughout the study, patients will be asked to strain urine for passage of calculus and note date and time of passage. Patients will also be asked to maintain a daily narcotic diary and complete a daily pain analog scale provided by our institution. Patients will be followed in the Urology Department's Stone Clinic with weekly imaging studies (KUB or CT scan) and renal function tests (serum creatinine) for 4 weeks.

Conditions

Ureteral Calculi

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

I

Celecoxib

Group Type: EXPERIMENTAL

celecoxib

Intervention Type: DRUG

Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.

II

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.

Interventions

celecoxib

Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.

Intervention Type: DRUG

Placebo

Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.

Intervention Type: OTHER

Other Intervention Names

Celebrex

Eligibility Criteria

Inclusion Criteria

• Ureteral calculus <= 10 mm in largest diameter
• Patient elects conservative management over immediate surgical intervention

Exclusion Criteria

• Solitary kidney
• Renal insufficiency (creatinine [CR] > 1.8)
• Urinary infection (fever > 101 degrees Fahrenheit, positive urine culture, many bacteria on urinalysis)
• Allergic-type reactions to sulfonamides
• Patients with known hypersensitivity to celecoxib
• Patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or nonsteroidal anti-inflammatory agents (NSAIDs)
• Prior history of gastrointestinal (GI) bleed or active gastric ulcer disease
• Pregnancy/nursing
• Moderate-severe hepatic dysfunction (Child-Pugh Classification B or C)
• Concomitant use of drugs that inhibit P450 2C9, drugs metabolized by P450 2D6, ACE inhibitors, furosemide, warfarin (and other anticoagulants, not including low-dose aspirin), fluconazole, or lithium
• Women of child-bearing age unwilling to use effective contraception for the duration of the trial.
• Significant or unstable cardiovascular disease defined as:

• myocardial infarction or stroke less than 3 months prior to the study randomization
• planned revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass surgery [CABG]) at the time of study screening
• angina at rest or uncontrolled angina
• hospitalization or emergency department visits for cardiac-related illness less than 3 months prior to randomization
• uncontrolled hypertension (defined as systolic blood pressure [BP] > 140 mmHg and/or diastolic BP > 90 mmHg at the baseline visit)
• evidence of cardiac electrophysiologic instability including history of uncontrolled complex ventricular arrhythmia, uncontrolled atrial fibrillation or flutter, or uncontrolled supraventricular tachycardias with a ventricular response heart rate of > 100 beats per minute (BPM) at rest. (Subjects whose cardiac electrophysiologic instability is controlled with a pacemaker or implantable cardioverter defibrillator (ICD) are eligible.)
• symptoms, signs or treatment for congestive heart failure (CHF) or known left ventricular dysfunction with ejection fraction < 40%
• undergone coronary bypass surgery or any major surgery (cardiac or noncardiac) or trauma within the past 3 months

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pfizer

INDUSTRY

Sponsor Role: collaborator

University of Minnesota

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Manoj Monga, MD

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota

Locations

University of Minnesota

Minneapolis, Minnesota, United States

Countries

United States

Other Identifiers

3485B

Identifier Type: -

Identifier Source: secondary_id

0405M60562

Identifier Type: -

Identifier Source: org_study_id